Revolution Medicines RVMD
$ 56.71
-0.13%
Quarterly report 2024-Q3
added 11-06-2024
Country |
USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Mark A. Goldsmith M.D., Ph.D. |
Employees in the company |
117 |
Shares |
113 M |
Market Cap[1] |
$ 6.42 B |
EBITDA (LTM) |
$ -590 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.